We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Automated Microfluidic Device Simultaneously Detects HIV RNA and Antibodies

By LabMedica International staff writers
Posted on 27 Mar 2016
Print article
Diagnostic laboratories now have available a fully automated molecular testing device that simultaneously detects host anti-HIV antibodies and viral RNA in a single specimen of saliva or blood.

In developing the system, Rheonix Inc. (Ithaca, NY, USA) optimized a commercially available HIV serologic assay to run within a microfluidic device into which was also incorporated an isothermal LAMP assay to detect the presence of viral RNA. LAMP (Loop-mediated isothermal AMPlification) is highly regarded for its rapidity, sensitivity, and ability to amplify both DNA and RNA.

The finalized system consisted of a disposable injection molded and film-laminated microfluidic CARD (Chemistry and Reagent Device) disposable device and a portable, software controlled instrument, which together automatically performed all steps of both assays without any user intervention after the initial loading of samples and reagents.

The microfluidic CARD cartridge had multiple microchannels, valves, pumps, and reservoirs, which performed the immunoassay, isolated viral RNA for detection by magnetic bead based purification, and Reverse Transcriptase loop-mediated isothermal amplification (RT-LAMP). The microfluidic system was able to detect host anti-HIV antibodies and viral RNA simultaneously in up to four blood or saliva samples.

The system was shown to detect acute HIV infection and allow immediate confirmation of a seropositive screening result by detection of HIV RNA. It also addressed the well-known "seroconversion window" during early HIV infection when antibodies are not yet detectable and viral loads are at their highest.

“Our technology meets the needs of settings with limited resources. The assays are rapid, sensitive, specific, easy to perform, and inexpensive,” said Dr. Greg Galvin, CEO of Rheonix. “This combined HIV screening and confirmatory test will have a significant commercial and social impact that we’re excited to see materialize.”

The assay device was described in detail in the January 31, 2016, online edition of the Journal of AIDS & Clinical Research.

Related Links:

Rheonix Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more


view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more


view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.